Notably, CellSearchTM (Veridex)13, approved for clinical use in breast, colorectal, and prostate cancer patients, enriches the content of CTCs by using a magnetic ferrofluid containing antibodies against epithelial cell adhesion molecule (EpCAM). This evidence concerns the gene EPCAM and prostate cancer.